Guideline for clinical management of adverse reactions of bacillus Calmette-Guérin

doi:10.3969/j.issn.1000-6621.2021.06.002

Abstract

Abstract:

Bacillus Calmette-Guérin (BCG) is a live attenuated vaccine against tuberculosis, and is one of the most widely used and safest vaccines in the world. The prevalence and mortality of miliary tuberculosis and tuberculous meningitis in children have significantly decreased since being vaccinated with BCG from 1978 in China. BCG is applicated in the prevention of tuberculosis, in addition, it is also commonly used in perfusion therapy for bladder carcinoma in situ. BCG instillation helps to reduce and delay the recurrence and progression of non-muscle invasive bladder carcinoma, it is considered as the best intravesical instillation drug at present. However, due to the production process, the virulence of the vaccine, the methods of usage of the vaccine, individual differences and other factors, the adverse reactions after BCG vaccination and perfusion often occur. The clinical treatment of BCG adverse reactions has not been standardized by now. Therefore, the Tuberculosis Branch of Chinese Medical Association, the School and Children Tuberculosis Branch of Chinese Antituberculosis Association organized some experts to formulated the “Guideline for Clinical Treatment of BCG Adverse Reactions” after discussions. The guideline includes the types of BCG, the methods of usage, and clinical characteristics, diagnostic criteria, treatment and prevention of the adverse reactions of BCG vaccine, in order to standardize with the treatment for the adverse reactions of BCG.

Key words: BCG vaccine, Drug toxicity, Therapeutic uses, Guidebooks

. Guideline for clinical management of adverse reactions of bacillus Calmette-Guérin[J]. Chinese Journal of Antituberculosis, 2021, 43(6): 532-538. doi: 10.3969/j.issn.1000-6621.2021.06.002

References 47

[1]	Calmette A. Preventive vaccination against tuberculosis with BCG. Proc R Soc Med, 1931,24(11):1481-1490. pmid: 19988326
[2]	Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis, 2014,58(4):470-480. doi: 10.1093/cid/cit790. doi: 10.1093/cid/cit790 URL
[3]	World Health Organization. BCG vaccine: WHO position paper, February 2018-Recommendations. Vaccine, 2018,36(24):3408-3410. doi: 10.1016/j.vaccine.2018.03.009. doi: S0264-410X(18)30345-1 pmid: 29609965
[4]	中华人民共和国国家卫生和计划生育委员会疾病预防控制局. 国家卫生计生委办公厅关于印发国家免疫规划儿童免疫程序及说明(2016年版)的通知. 国卫办疾控发〔2016〕52号. 2016-12-06.
[5]	潘家国. 卡介苗接种实用手册. 南京: 东南大学出版社, 2006: 94-95.
[6]	吴克长. 130例BCG接种后局部异常反应原因分析. 中国热带医学, 2008,8(10):1822.
[7]	World Health Organization. Information sheet observed rate of vaccine reactions Bacillus Calmette-Guérin (BCG) vaccine. Geneva: World Health Organization, 2012.
[8]	Elsidig N, Alshahrani D, Alshehri M, et al. Bacillus Calmette-Guérin vaccine related lymphadenitis in children: Management guidelines endorsed by the Saudi Pediatric Infectious Diseases Society (SPIDS). Int J Pediatr Adolesc Med, 2015,2(2):89-95. doi: 10.1016/j.ijpam.2015.05.003. doi: 10.1016/j.ijpam.2015.05.003 URL
[9]	Venkataraman A, Yusuff M, Liebeschuetz S, et al. Management and outcome of Bacille Calmette-Guérin vaccine adverse reactions. Vaccine, 2015,33(41):5470-5474. doi: 10.1016/j.vaccine.2015.07.103. doi: S0264-410X(15)01107-X pmid: 26275478
[10]	Li T, Zhou X, Ling Y, et al. Genetic and Clinical Profiles of Disseminated Bacillus Calmette-Guérin Disease and Chronic Granulomatous Disease in China. Front Immunol, 2019,10:73. doi: 10.3389/fimmu.2019.00073. doi: 10.3389/fimmu.2019.00073 URL
[11]	Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol, 2014,133(4):1134-1141. doi: 10.1016/j.jaci.2014.02.028. doi: 10.1016/j.jaci.2014.02.028 URL
[12]	de la Morena MT, Leonard D, Torgerson TR, et al. Long-term outcomes of 176 patients with X-linked hyper-IgM syndrome treated with or without hematopoietic cell transplantation. J Allergy Clin Immunol, 2017,139(4):1282-1292. doi: 10.1016/j.jaci.2016.07.039. doi: 10.1016/j.jaci.2016.07.039 URL
[13]	Bustamante J, Boisson-Dupuis S, Abel L, et al. Mendelian susceptibility to mycobacterial disease: genetic, immunological, and clinical features of inborn errors of IFN-gamma immunity. Semin Immunol, 2014,26(6):454-470. doi: 10.1016/j.smim.2014.09.008. doi: 10.1016/j.smim.2014.09.008 URL
[14]	卢水华, 李涛, 席秀红, 等. 播散性卡介菌病23例分析. 中华传染病杂志, 2013,31(7):417-421. doi: 10.3760/cma.j.issn.1000-6680.2013.07.009. doi: 10.3760/cma.j.issn.1000-6680.2013.07.009
[15]	Aronson JK. Meyler’s Side Effects of Drugs. 16th ed. Amsterdam: Elsevier, 2016: 797-806.
[16]	Casanova JL, Jouanguy E, Lamhamedi S, et al. Immunological conditions of children with BCG disseminated infection. Lancet, 1995,346(8974):581. doi: 10.1016/s0140-6736(95)91421-8. doi: 10.1016/s0140-6736(95)91421-8 pmid: 7658805
[17]	赵爱华, 寇丽杰, 乔来艳, 等. 卡介菌及其衍生制品鉴别实验用BCG DNA国家参考品的研制. 中国药事, 2010,24(3):244-247.
[18]	赵爱华, 寇丽杰, 徐苗, 等. 我国皮内注射用卡介苗使用说明书修订意见. 中国防痨杂志, 2014,36(10):863-867. doi: 10.3969/j.issn.1000-6621.2014.10.001. doi: 10.3969/j.issn.1000-6621.2014.10.001
[19]	夏露, 卢水华, 李锋. 母牛分枝杆菌菌苗治疗卡介苗反应性淋巴结炎临床分析. 中国防痨杂志, 2016,38(3):189-192. doi: 10.3969/j.issn.1000-6621.2016.03.007. doi: 10.3969/j.issn.1000-6621.2016.03.007
[20]	Suliman OM, Ahmed MJ, Bilal JA. Clinical characteristics and needle aspiration management of Bacillus Calmette-Guérin lymphadenitis in children. Saudi Med J, 2015,36(3):280-285. doi: 10.15537/smj.2015.3.10294. doi: 10.15537/smj.2015.3.10294 pmid: 25737168
[21]	Kilic SS, Hacimustafaoglu M, Boisson-Dupuis S, et al. A patient with tyrosine kinase 2 deficiency without hyper-IgE syndrome. J Pediatr, 2012,160(6):1055-1057. doi: 10.1016/j.jpeds.2012.01.056. doi: 10.1016/j.jpeds.2012.01.056 URL
[22]	Hatipoglu N, Güvenç BH, Deswarte C, et al. Inherited IL-12Rβ1 Deficiency in a Child With BCG Adenitis and Oral Candidiasis: A Case Report. Pediatrics, 2017,140(5):e20161668. doi: 10.1542/peds.2016-1668. doi: 10.1542/peds.2016-1668 URL
[23]	Aelami MH, Alborzi A, Pouladfar G, et al. Post-Vaccination Disseminated Bacillus Calmette Guerin Infection Among Children in Southern Iran. Jundishapur J Microbiol, 2015,8(11):e25663. doi: 10.5812/jjm.25663. doi: 10.5812/jjm.25663
[24]	Roglic'S , Dickson D, Miše B, et al. Successful Treatment of Disseminated Bacillus Calmette-Guérin Disease in an HIV-Infected Child with a Linezolid-Containing Regimen. Case Rep Infect Dis, 2016,2016:1528981. doi: 10.1155/2016/1528981. doi: 10.1155/2016/1528981
[25]	中华医学会儿科学分会免疫学组, 《中华儿科杂志》编辑委员会. 原发性免疫缺陷病抗感染治疗与预防专家共识. 中华儿科杂志, 2017,55(4):248-255. doi: 10.3760/cma.j.issn.0578-1310.2017.04.003. doi: 10.3760/cma.j.issn.0578-1310.2017.04.003
[26]	Sriaroon P, Ballow M. Immunoglobulin Replacement Therapy for Primary Immunodeficiency. Immunol Allergy Clin North Am, 2015,35(4):713-730. doi: 10.1016/j.iac.2015.07.006. doi: 10.1016/j.iac.2015.07.006 pmid: 26454315
[27]	Wasserman RL. Personalized Therapy: Immunoglobulin Replacement for Antibody Deficiency. Immunol Allergy Clin North Am, 2019,39(1):95-111. doi: 10.1016/j.iac.2018.08.001. doi: S0889-8561(18)30071-7 pmid: 30466775
[28]	Lacerda-Pontes R, Gomes LN, Albuquerque RS, et al. The extended understanding of chronic granulomatous disease. Curr Opin Pediatr, 2019,31(6):869-873. doi: 10.1097/MOP.0000000000000830. doi: 10.1097/MOP.0000000000000830
[29]	Lum SH, Hoenig M, Gennery AR, et al. Conditioning Regimens for Hematopoietic Cell Transplantation in Primary Immunodeficiency. Curr Allergy Asthma Rep, 2019,19(11):52. doi: 10.1007/s11882-019-0883-1. doi: 10.1007/s11882-019-0883-1 pmid: 31741098
[30]	Shamriz O, Chandrakasan S. Update on Advances in Hematopoietic Cell Transplantation for Primary Immunodeficiency Disorders. Immunol Allergy Clin North Am, 2019,39(1):113-128. doi: 10.1016/j.iac.2018.08.003. doi: S0889-8561(18)30073-0 pmid: 30466768
[31]	Fernandes JF, Nichele S, Daudt LE, et al. Transplantation of Hematopoietic Stem Cells for Primary Immunodeficiencies in Brazil: Challenges in Treating Rare Diseases in Developing Countries. J Clin Immunol, 2018,38(8):917-926. doi: 10.1007/s10875-018-0564-1. doi: 10.1007/s10875-018-0564-1 URL
[32]	Booth C, Romano R, Roncarolo MG, et al. Gene therapy for primary immunodeficiency. Hum Mol Genet, 2019,28(R1):R15-R23. doi: 10.1093/hmg/ddz170. doi: 10.1093/hmg/ddz170 URL
[33]	Cavazzana M, Bushman FD, Miccio A, et al. Gene therapy targeting haematopoietic stem cells for inherited diseases: progress and challenges. Nat Rev Drug Discov, 2019,18(6):447-462. doi: 10.1038/s41573-019-0020-9. doi: 10.1038/s41573-019-0020-9 pmid: 30858502
[34]	肖桂荣, 张莹, 马晴, 等. 国内外结核病诊疗指南中关于抗结核药物相互作用管理的分析. 华西医学, 2015,30(5):954-958. doi: 10.7507/1002-0179.20150273. doi: 10.7507/1002-0179.20150273
[35]	Carneiro-Sampaio M, Jacob CM, Leone CR. A proposal of warning signs for primary immunodeficiencies in the first year of life. Pediatr Allergy Immunol, 2011,22(3):345-346. doi: 10.1111/j.1399-3038.2010.01084.x. doi: 10.1111/j.1399-3038.2010.01084.x pmid: 21457340
[36]	Thaventhiran JED, Lango Allen H, Burren OS, et al. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature, 2020,583(7814):90-95. doi: 10.1038/s41586-020-2265-1. doi: 10.1038/s41586-020-2265-1 pmid: 32499645
[37]	Seleman M, Hoyos-Bachiloglu R, Geha RS, et al. Uses of Next-Generation Sequencing Technologies for the Diagnosis of Primary Immunodeficiencies. Front Immunol, 2017,8:847. doi: 10.3389/fimmu.2017.00847. doi: 10.3389/fimmu.2017.00847 URL
[38]	Kanegane H, Hoshino A, Okano T, et al. Flow cytometry-based diagnosis of primary immunodeficiency diseases. Allergol Int, 2018,67(1):43-54. doi: 10.1016/j.alit.2017.06.003. doi: 10.1016/j.alit.2017.06.003 URL
[39]	Al-Hammadi S, Alsuwaidi AR, Alshamsi ET, et al. Disseminated Bacillus Calmette-Guérin (BCG) infections in infants with immunodeficiency. BMC Res Notes, 2017,10(1):177. doi: 10.1186/s13104-017-2499-7. doi: 10.1186/s13104-017-2499-7 pmid: 28476145
[40]	Alsuhaibani M, Felimban G, Shoukri M, et al. Safety and tolerability of moxifloxacin for the treatment of disseminated BCGitis in children. Int J Pediatr Adolesc Med, 2019,6(2):47-50. doi: 10.1016/j.ijpam.2019.01.003. doi: 10.1016/j.ijpam.2019.01.003 URL
[41]	Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol, 2014,133(4):1134-1141. doi: 10.1016/j.jaci.2014.02.028. doi: 10.1016/j.jaci.2014.02.028 URL
[42]	中国研究型医院学会泌尿外科学专业委员会, 中国医疗保健国际交流促进会泌尿健康促进分会, 中国医疗保健国际交流促进会循证医学分会, 等. 中国非肌层浸润性膀胱癌治疗与监测循证临床实践指南(2018年标准版). 现代泌尿外科杂志, 2019,24(7):516-542. doi: 10.3969/j.issn.1009-8291.2019.07.004. doi: 10.3969/j.issn.1009-8291.2019.07.004
[43]	Kaburaki K, Sugino K, Sekiya M, et al. Miliary Tuberculosis that Developed after Intravesical Bacillus Calmette-Guerin Therapy. Intern Med, 2017,56(12):1563-1567. doi: 10.2169/internalmedicine.56.8055. doi: 10.2169/internalmedicine.56.8055 URL
[44]	Rachakonda T, Kendall B, Spivak AM, et al. Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer. Open Forum Infect Dis, 2017, 4(3):ofx126. doi: 10.1093/ofid/ofx126. doi: 10.1093/ofid/ofx126
[45]	To U, Kim J, Chia D. Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment. Case Rep Med, 2014,2014:362845. doi: 10.1155/2014/362845. doi: 10.1155/2014/362845
[46]	Golub V, Malhotra P, Patel S. Mycobacterial brain tuberculomas due to Bacille Calmette-Guérin intravesical chemotherapy for bladder cancer: A case report and literature review. Can J Infect Dis Med Microbiol, 2011,22(3):104-106. doi: 10.1155/2011/869286. doi: 10.1155/2011/869286 URL
[47]	Pérez-Jacoiste Asín MA, Fernández-Ruiz M, López-Medrano F, et al. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore), 2014,93(17):236-254. doi: 10.1097/MD.0000000000000119. doi: 10.1097/MD.0000000000000119 pmid: 25398060